DOCSLIB.ORG

Alfaxan® Faqs

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Alfaxan® Faqs The use of one premedicant or a combination of premedicants often reduces the dose of the Summary of Product Characteristics veterinary medicinal product required. Premedication with alpha-2-adrenoceptor agonists References such as xylazine and medetomidine can markedly increase the duration of anaesthesia in a 1. Jurox and Ricera, An in vitro study evaluating the binding of alfaxalone protocol for canine surgical patients. 2009, Faculty of Veterinary 1. Name of the veterinary medicinal product ALFAXAN 10 mg/ml solution for injection for dose dependent fashion. In order to shorten recovery periods it may be desirable to reverse dogs, cats and pet rabbits 2. Qualitative and quantitative composition Active substance: the actions of these premedicants. Benzodiazepines should not be used as sole premedicants to various nuclear receptors (Ricera Study No. AA94464). Records in Medicine – University of Utrecht. alfaxalone 10 mg/ml For the full list of excipients, see section 6.1. 3. Pharmaceutical form Repeatable. Reliable. Relax. in dogs and cats as the quality of anaesthesia in some patients may be sub-optimal. House, 2010. 15. Jimenez, C.P., et al., Evaluation of the quality of recovery after Solution for injection Clear colourless solution 4. Clinical particulars 4.1 Target species Benzodiazepines may be used safely and effectively in combination with other premedicants Dogs, cats and non-food rabbits 4.2 Indications for use, specifying the target species As an and the veterinary medicinal product. Refer to section 4.3. 4.9 Amounts to be administered and 2. Jurox and Ricera, An in vitro study evaluating the binding of alfaxalone administration of propofol or alfaxalone for induction of anaesthesia induction agent prior to inhalation anaesthesia in cats, dogs and non food rabbits. As a sole administration route For intravenous use. Induction of anaesthesia: The induction dose of the to various abuse receptors (Ricera Study No. AA94047). Records in in dogs anaesthetized for magnetic resonance imaging. Veterinary anaesthetic agent for the induction and maintenance of anaesthesia for the performance veterinary medicinal product is based on data taken from controlled laboratory and field studies of examination or surgical procedures in cats and dogs. 4.3 Contraindications Do not use House, 2010. and is the amount of drug required for 9 of 10 patients (i.e. 90th percentile) to be successfully Anaesthesia and Analgesia, 2012. 39(2): p. 151-159. in combination with other intravenous anaesthetic agents. 4.4 Special warnings During induced for anaesthesia. Dosing recommendations for induction of anaesthesia are as follows: recovery, it is preferable that animals are not handled or disturbed. In dogs and cats, this 3. Muir, W., et al., The cardiorespiratory and anesthetic effects of clinical 16. Maddern, K., et al., Alfaxalone induction dose following administration may lead to paddling, minor muscle twitching or movements that are more violent. While DOGS CATS RABBITS and supraclinical doses of alfaxalone in cats. Veterinary Anaesthesia of medetomidine and butorphanol in the dog. Veterinary Anaesthesia better avoided, such reactions are clinically insignificant. 4.5 Special precautions for use and Analgesia, 2009. 36(1): p. 42-54. (i) Special precautions for use in animals The analgesic properties of alfaxalone are limited, Un-premedicated Premedicated Un-premedicated Premedicated Un-premedicated Premedicated and Analgesia, 2010. 37(1): p. 7-13. therefore appropriate peri-operative analgesia should be provided in cases where procedures mg/kg 3 2 5 5 5 4 4. Muir, W., et al., Cardiorespiratory and anesthetic effects of clinical and 17. Martinez Taboada, F. and P.J. Murison, Induction of anaesthesia with are anticipated to be painful. The safety of the veterinary medicinal product in animals less than 12 weeks of age (dogs and cats) and 16 weeks of age (rabbits) has not been demonstrated. mL/kg 0.3 0.2 0.5 0.5 0.5 0.4 supraclinical doses of alfaxalone in dogs. Veterinary Anaesthesia and alfaxalone or propofol before isoflurane maintenance in cats. Veterinary Transient post induction apnoea frequently occurs, particularly in dogs – see section 4.6 The dosing syringe should be prepared to contain the above dose. Administration should Analgesia, 2008. 35(6): p. 451-462. Record, 2010. 167(3): p. 85-89. for details. In such cases, endotracheal intubation and oxygen supplementation should be continue until the clinician is satisfied that the depth of anaesthesia is sufficient for employed. Facilities for intermittent positive pressure ventilation should be available. In 5. Whittem, T. and Pasloske, P., RD9604.03 – H005. Eight day target animal 18. Mathis, A., et al., Comparison of quality of recovery from anaesthesia endotracheal intubation, or until the entire dose has been administered. The necessary ® order to minimise the possibility of apnoea, administer the veterinary medicinal product by injection rate can be achieved by administration of one quarter (¼) of the calculated dose safety study of intravenous Alfaxan CD RTU in dogs administered every in cats induced with propofol or alfaxalone. Veterinary Anaesthesia and slow intravenous injection and not as a rapid dose. Especially when using higher doses of the every 15 seconds, so that the total dose, if required, would be administered over the first other day. 2004, Jurox Pty. Ltd. Analgesia, 2012. 39(3): p. 282-290. veterinary medicinal product, a dose-dependent respiratory depression may occur. Oxygen 60 seconds. If, 60 seconds after complete delivery of this first induction dose, intubation is and/or intermittent positive pressure ventilation should be administered to counteract still not possible, one further similar dose may be administered to effect. Maintenance of 6. Pasloske, K. and Whittem, T., JX9604.07-H004. A target animal safety 19. Murison, P.J. and F. Martinez Taboada, Effect of propofol and alfaxalone the threatening hypoxaemia/hypercapnea. This should be particularly important in risky anaesthesia: Following induction of anaesthesia with the veterinary medicinal product, the study in cats after administration of Alfaxan® CD RTU as single, anaesthetic cases and whenever the anaesthesia is to be carried out for a longer period of animal may be intubated and maintained on the veterinary medicinal product or an inhalation on pain after ovariohysterectomy in cats. Veterinary Record, 2010. time. In rabbits, oxygenation is essential before induction of anaesthesia and throughout the anaesthetic agent. In dogs and cats maintenance doses of the veterinary medicinal product repeated injections on days 0, 2 and 5 at doses of 5, 15 or 25 mg/kg. 166(11): p. 334-335. entire anaesthetic procedure to avoid potentially life threatening hypoxaemia. In dogs and may be given as supplemental boluses or as constant rate infusion. The veterinary medicinal 2004, 0n file at Jurox Pty Ltd. cats, the dose interval for maintenance of anaesthesia by intermittent bolus administration product has been used safely and effectively in dogs and cats for procedures lasting for up to 20. Psatha, E., et al., Clinical efficacy and cardiorespiratory effects of may require lengthening by more than 20%, or the maintenance dose by intravenous infusion one hour. The following doses suggested for maintenance of anaesthesia are based on data 7. Baron Strategic Services. Anaesthesia Market Research. Jurox vet survey may require reduction by more than 20%, when hepatic blood flow is severely diminished or alfaxalone, or diazepam/fentanyl for induction of anaesthesia in dogs taken from controlled laboratory and field studies and represent the average amount of drug hepatocellular injury is severe. In cats or dogs with renal insufficiency, doses for induction report Oct 11. On file at Jurox Pty. Ltd., Rutherford, NSW. Australia. that are a poor anaesthetic risk. Veterinary Anaesthesia and Analgesia, required to provide maintenance anaesthesia for each target species. However the actual and maintenance may require reduction. As with all general anaesthetic agents: It is advisable dose will be based on the response of the individual patient. Dosing recommendations for 8. Pasloske, K., et al., Plasma pharmacokinetics of alfaxalone in both 2011. 38: p. 24-36. to ensure that dogs and cats have been fasted before receiving the anaesthetic. Rabbits maintenance of anaesthesia are as follows: should not be fasted, but food should be removed one hour before anaesthesia. As with premedicated and un-premedicated Greyhound dogs after single, 21. Zaki, S., et al., Clinical evaluation of Alfaxan-CD® as an intravenous ® other intravenous anaesthetic agents, caution should be exercised in animals with cardiac DOGS CATS intravenous administration of Alfaxan at a clinical dose. Journal of or respiratory impairment, or in hypovolaemic or debilitated animals. Additional monitoring anaesthetic in young cats. Australian Veterinary Journal, 2009. 87(3): is advised and particular attention should be paid to respiratory parameters in aged animals, Un-premedicated Premedicated Un-premedicated Premedicated Veterinary Pharmacology and Therapeutics, 2009. 32: p. 510-513. p. 82-87. or in cases where there may be additional physiological stress imposed by pre-existing Dose for constant rate infusion 9. Metcalfe, S., et al., A multi-centre clinical trial evaluating the efficacy pathology, shock or caesarean section. Following induction of anaesthesia, the use of an 22. Child, K.J., et al., Metabolism and excretion of CT1341 in the rat. mg/kg/hour 8 - 9 6 - 7 10 - 11 7 - 8 ® endotracheal tube is recommended to maintain airway patency. It is advisable to administer and safety of Alfaxan administered to bitches for induction of In Steroid Anaesthesia, 1972. Royal College of Physicians, London. supplemental oxygen during maintenance of anaesthesia. Respiratory embarrassment may mg/kg/minute 0.13 - 0.15 0.10 - 0.12 0.16 - 0.18 0.11 - 0.13 anaesthesia prior to caesarean section. In 33rd World small Animal occur – ventilation of the lungs with oxygen should be considered if haemoglobin saturation mL/kg/minute 0.013 - 0.015 0.010 - 0.012 0.016 - 0.018 0.011 - 0.013 Congress. 2008. Dublin, Ireland: WSAVA/FECAVA.
Load more

Recommended publications
  • 268 Part 522—Implantation Or Injectable Dosage Form
    § 520.2645 21 CFR Ch. I (4–1–18 Edition) (ii) Indications for use. For the control 522.82 Aminopropazine. of American foulbrood (Paenibacillus 522.84 Beta-aminopropionitrile. larvae). 522.88 Amoxicillin. 522.90 Ampicillin injectable dosage forms. (iii) Limitations. The drug should be 522.90a Ampicillin trihydrate suspension. fed early in the spring or fall and con- 522.90b Ampicillin trihydrate powder for in- sumed by the bees before the main jection. honey flow begins, to avoid contamina- 522.90c Ampicillin sodium. tion of production honey. Complete 522.144 Arsenamide. treatments at least 4 weeks before 522.147 Atipamezole. main honey flow. 522.150 Azaperone. 522.161 Betamethasone. [40 FR 13838, Mar. 27, 1975, as amended at 50 522.163 Betamethasone dipropionate and FR 49841, Dec. 5, 1985; 59 FR 14365, Mar. 28, betamethasone sodium phosphate aque- 1994; 62 FR 39443, July 23, 1997; 68 FR 24879, ous suspension. May 9, 2003; 70 FR 69439, Nov. 16, 2005; 73 FR 522.167 Betamethasone sodium phosphate 76946, Dec. 18, 2008; 75 FR 76259, Dec. 8, 2010; and betamethasone acetate. 76 FR 59024, Sept. 23, 2011; 77 FR 29217, May 522.204 Boldenone. 17, 2012; 79 FR 37620, July 2, 2014; 79 FR 53136, 522.224 Bupivacaine. Sept. 8, 2014; 79 FR 64116, Oct. 28, 2014; 80 FR 522.230 Buprenorphine. 34278, June 16, 2015; 81 FR 48702, July 26, 2016] 522.234 Butamisole. 522.246 Butorphanol. § 520.2645 Tylvalosin. 522.275 N-Butylscopolammonium. 522.300 Carfentanil. (a) Specifications. Granules containing 522.304 Carprofen. 62.5 percent tylvalosin (w/w) as 522.311 Cefovecin.
    [Show full text]
  • Effects of Alfaxalone Or Propofol on Giant-Breed Dog Neonates Viability
    animals Article Effects of Alfaxalone or Propofol on Giant-Breed Dog Neonates Viability During Elective Caesarean Sections Monica Melandri 1, Salvatore Alonge 1,* , Tanja Peric 2, Barbara Bolis 3 and Maria C Veronesi 3 1 Società Veterinaria “Il Melograno” Srl, 21018 Sesto Calende, Varese, Italy; [email protected] 2 Department of Agricultural, Food, Environmental and Animal Sciences, University of Udine, 33100 Udine, Italy; [email protected] 3 Department of Veterinary Medicine, Università degli Studi di Milano, 20100 Milan, Italy; [email protected] (B.B.); [email protected] (M.C.V.) * Correspondence: [email protected]; Tel.: +39-392-805-8524 Received: 20 September 2019; Accepted: 7 November 2019; Published: 13 November 2019 Simple Summary: Nowadays, thanks to the increased awareness of owners and breeders and to the most recent techniques available to veterinarians, the management of parturition, especially of C-sections, has become a topic of greater importance. Anesthesia is crucial and must be targeted to both the mother and neonates. The present study aimed to evaluate the effect of the induction agent alfaxalone on the vitality of puppies born from elective C-section, in comparison to propofol. After inducing general anesthesia for elective C-section, puppies from the mothers induced with alfaxalone had higher 5-min Apgar scores than those induced with propofol. The concentration of cortisol in fetal fluids collected at birth is neither influenced by the anesthetic protocol used, nor does it differ between amniotic and allantoic fluids. Nevertheless, the cortisol concentration in fetal fluids affects the relationship between anesthesia and the Apgar score: the present study highlights a significant relationship between the anesthetic protocol used and Apgar score in puppies, and fetal fluids cortisol concentration acts as a covariate of this relationship.
    [Show full text]
  • The Cardiorespiratory and Anesthetic Effects of Clinical and Supraclinical
    THE CARDIORESPIRATORY AND ANESTHETIC EFFECTS OF CLINICAL AND SUPRA CLINICAL DOSES OF ALF AXALONE IN CYCLODEXTRAN IN CATS AND DOGS DISSERTATION Presented in Partial Fulfillment of the Requirements for the Degree Master of Science in the Graduate School of The Ohio State University By Laura L. Nelson, B.S., D.V.M. * * * * * The Ohio State University 2007 Dissertation Committee: Professor Jonathan Dyce, Adviser Professor William W. Muir III Professor Shane Bateman If I have seen further, it is by standing on the shoulders of giants. lmac Ne1vton (1642-1727) Copyright by Laura L. Nelson 2007 11 ABSTRACT The anesthetic properties of steroid hormones were first identified in 1941, leading to the development of neurosteroids as clinical anesthetics. CT-1341 was developed in the early 1970’s, featuring a combination of two neurosteroids (alfaxalone and alphadolone) solubilized in Cremophor EL®, a polyethylated castor oil derivative that allows hydrophobic compounds to be carried in aqueous solution as micelles. Though also possessing anesthetic properties, alphadolone was included principally to improve the solubility of alfaxalone. CT-1341, marketed as Althesin® and Saffan®, was characterized by smooth anesthetic induction and recovery in many species, a wide therapeutic range, and no cumulative effects with repeated administration. Its cardiorespiratory effects in humans and cats were generally mild. However, it induced severe hypersensitivity reactions in dogs, with similar reactions occasionally occurring in cats and humans. The hypersensitivity reactions associated with this formulation were linked to Cremophor EL®, leading to the discontinuation of Althesin® and some other Cremophor®-containing anesthetics. More recently, alternate vehicles for hydrophobic drugs have been developed, including cyclodextrins.
    [Show full text]
  • Intravenous Alfaxalone Anaesthesia in Two Squamate Species: Eublepharis Macularius and Morelia Spilota Cheynei
    INTRAVENOUS ALFAXALONE ANAESTHESIA IN TWO SQUAMATE SPECIES: EUBLEPHARIS MACULARIUS AND MORELIA SPILOTA CHEYNEI Tesi per il XXIX Ciclo del Dottorato in Scienze Veterinarie, Curriculum Scienze Cliniche Veterinarie Dipartimento di Scienze Veterinarie, Universita’ degli Studi di Messina Tutor: Prof. Filippo Spadola Cotutor: Prof. Zdenek Knotek Dr. Manuel Morici Sommario L’anestesia negli Squamati è una costante sfida della medicina e chirurgia dei rettili. Le differenze morfo-fisiologiche di questi taxa, rendono difficilmente applicabile i comuni concetti di anestesiologia veterinaria usati con successo negli altri animali da compagnia. Diversi protocolli anestetici sono stati utilizzati, sia per l’induzione che per il mantenimento, sia negli ofidi che nei sauri, ma con risultati variabili. Di fatti la maggior parte dei protocolli risultano in induzione o recuperi troppo brevi o troppo lunghi. L’obbiettivo di questa tesi dottorale è di valutare l’efficacia di un anestetico steroideo (alfaxalone), somministrato per via endovenosa in due specie di squamati usati come modello: il geco leopardo (Eublepharis macularius) e il pitone tappeto (Morelia spilota cheynei). Due metodi di somministrazione endovenosa (vena giugulare nei gechi e vena caudale nei serpenti) sono stati analizzati e descritti, usando un dosaggio di anestetico di 5 mg/kg in 20 gechi leopardo, e di 10 mg/kg in 10 pitoni tappeto. Nei gechi il tempo di induzione, il tempo di perdita del tono mandibolare, l’intervallo di anestesia chirurgica e il recupero completo sono stati rispettivamente di 27.5 ± 30.7 secondi, 1.3 ± 1.4 minuti, 12.5 ± 2.2 minuti and 18.8 ± 12.1 minuti. Nei pitoni tappeto, il tempo di induzione, la perdita di sensazione, il tempo di inserimento del tubo endotracheale, l’intervallo di anestesia chirurgica e il recupero sono stati rispettivamente di 3.1±0.8 minuti, 5.6±0.7 minuti, 6.9±0.9 minuti, 18.8±4.7 minuti, e 36.7±11.4 minuti.
    [Show full text]
  • 240 Part 522—Implantation Or Injectable Dosage Form
    § 520.2645 21 CFR Ch. I (4–1–14 Edition) feed; and for the control of porcine pro- (3) Limitations. Federal law restricts liferative enteropathies (PPE, ileitis) this drug to use by or on the order of a associated with Lawsonia intracellularis licensed veterinarian. when followed immediately by tylosin [77 FR 55415, Sept. 10, 2012] phosphate medicated feed. (B) For the treatment and control of PART 522—IMPLANTATION OR swine dysentery associated with Brachyspira hyodysenteriae. INJECTABLE DOSAGE FORM NEW (iii) Limitations. Prepare a fresh solu- ANIMAL DRUGS tion daily. Do not administer within 48 Sec. hours of slaughter. As indicated in 522.23 Acepromazine. paragraph (d)(3)(ii)(A) of this section, 522.52 Alfaxalone. follow with tylosin phosphate medi- 522.56 Amikacin. cated feed as in § 558.625(f)(1)(vi)(c) of 522.62 Aminopentamide. this chapter. 522.82 Aminopropazine. (4) Honey bees—(i) Amount. Mix 200 522.84 Beta-aminopropionitrile. milligrams tylosin in 20 grams confec- 522.88 Amoxicillin. 522.90 Ampicillin injectable dosage forms. tioners’/powdered sugar. Use imme- 522.90a Ampicillin trihydrate suspension. diately. Apply (dust) this mixture over 522.90b Ampicillin trihydrate powder for in- the top bars of the brood chamber once jection. weekly for 3 weeks. 522.90c Ampicillin sodium. (ii) Indications for use. For the control 522.144 Arsenamide. of American foulbrood (Paenibacillus 522.147 Atipamezole. 522.150 Azaperone. larvae). 522.161 Betamethasone. (iii) Limitations. The drug should be 522.163 Betamethasone dipropionate and fed early in the spring or fall and con- betamethasone sodium phosphate aque- sumed by the bees before the main ous suspension.
    [Show full text]
  • Anesthesia During Gestation and Its Effects on Newborn
    Scientific Works. Series C. Veterinary Medicine. Vol. LXIII (1) ISSN 2065-1295; ISSN 2343-9394 (CD-ROM); ISSN 2067-3663 (Online); ISSN-L 2065-1295 increased cardiac work, and decreased an endotheliochorial and zonary type of peripheral vascular resistance. Other changes placenta (Miglino et al., 2006; Furukawa et al., ANESTHESIA DURING GESTATION AND ITS EFFECTS are respiratory, represented by decreased FRC, 2014). Most anesthetics cross the placenta and ON NEWBORN VIABILITY decreased total lung volume, increased minute the blood-brain barrier of the fetus. The ventilation and oxygen consumption, and permeability of the placenta differs depending Andra DEGAN, Dragoș BÎRȚOIU, Alexandru ȘONEA, Ruxandra COSTEA decreased PaCO2 (Ryan, Wagner, 2006; on type of placenta and the physicochemical Lemke, 2007; Branson, 2007). Dams and properties of the drugs. The endotheliochorial University of Agronomic Science and Veterinary Medicine, Faculty of Veterinary Medicine fetuses have an increased metabolic demand, placenta present in canines allows close Bucharest, 59 Marasti Blvd., District 1, Bucharest, Romania leading to a maternal blood volume increases maternal-fetal contact which facilitates the of approximately 40%. Plasma volume increase passive passage of drugs. Placental transfer of Corresponding author email: [email protected] is proportionally greater than the increase in drugs can occur by several mechanisms; by far, erythrocytes, leading to hemodilution and the most important is simple diffusion. Abstract: relative anemia (Seymour, 1999; Pascoe, Diffusion across the placenta is determined by During the gestation period, canine females go through physiological changes which can influence the way the Moon, 2001). A greater number of fetuses will molecular weight, the degree to which the drug anesthetics are absorbed, metabolized and excreted.
    [Show full text]
  • Alfaxan® User Guide
    Repeatable. Reliable. Relax. Alfaxan® User Guide Pre-anaesthetic assessment to recovery PRE-ANAESTHETIC ASSESSMENT INDUCTION TRANSITION Full clinical examination Draw up the full dose of Alfaxan® Connect to appropriate breathing system 2 mg/kg (0.2 mL/kg) for dogs CHECK FOR... LOOK OUT Suitable for anaesthesia? 5 mg/kg (0.5mL/kg) for cats FOR... 4 mg/kg (0.4 mL/kg) for rabbits YES NO Label the syringe Spontaneous ventilation? Take a ‘pre-induction’ Assign ASA score Further tests? heart rate YES NO Stabilise ASA PHYSICAL STATUS Re-assess CLASSIFICATION SYSTEM (Consider referral?) Secure IV access Ensure catheter is The five physical risk states are: intravenous and patent Supply maintenance Wait. If SPO2 ASA Physical Status 1 A normal healthy patient • Early plane of sedation agent and / or clinical signs indicate the ASA Physical Status 2 A patient with mild systemic disease Give ¼ of the induction dose • Degree of control Breathing need, start IPPV ASA Physical Status 3 A patient with severe systemic disease over the animal (Likely to be continuous) ASA Physical Status 4 A patient with severe systemic disease that is WAIT 15 SECONDS Heart Rate a constant threat to life (Alfaxan® is thought to LOOK OUT FOR... ASA Physical Status 5 A moribund patient who is not expected to Give another ¼ dose minimally affect cardiac survive without the operation function at clinical doses) If the animal has been presented as an emergency, the letter ‘E’ can be added to the recorded stage. WAIT 15 SECONDS Anaesthetic Depth • Adequate duration of action for It is essential that all patients are classified before any premedication is applied, and that smooth & unhurried transition consideration is paid to the classification in developing the patient’s anaesthetic protocol.
    [Show full text]
  • Accepted Manuscript
    Accepted Manuscript A clinical evaluation of the pharmacokinetics and pharmacodynamics of intravenous alfaxalone in cyclodextrin in male and female rats following a loading dose and constant rate infusion Kate L. White, Stuart Paine, John Harris PII: S1467-2987(17)30062-4 DOI: 10.1016/j.vaa.2017.01.001 Reference: VAA 88 To appear in: Veterinary Anaesthesia and Analgesia Please cite this article as: White KL, Paine S, Harris J, A clinical evaluation of the pharmacokinetics and pharmacodynamics of intravenous alfaxalone in cyclodextrin in male and female rats following a loading dose and constant rate infusion, Veterinary Anaesthesia and Analgesia (2017), doi: 10.1016/ j.vaa.2017.01.001. This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. provided by Nottingham ePrints View metadata, citation and similar papers at core.ac.uk CORE brought to you by 1 ACCEPTED MANUSCRIPT 1 RESEARCH PAPER 2 A clinical evaluation of the pharmacokinetics and pharmacodynamics of 3 intravenous alfaxalone in cyclodextrin in male and female rats following a loading 4 dose and constant rate infusion 5 Kate L White*, Stuart Paine* & John Harris† 6 7 *School of Veterinary Medicine and Science, University of Nottingham, Sutton 8 Bonington, UK 9 †School of Biosciences, University of Nottingham, Sutton Bonington, UK 10 11 Correspondence: Kate White, School of Veterinary Medicine and Science, University 12 of Nottingham, Sutton Bonington, Loughborough, Leics LE12 5RD, UK.
    [Show full text]
  • Alfaxalone Activates Human Pregnane-X Receptors with Greater Efficacy Than Allopregnanolone: an In-Vitro Study with Implications for Neuroprotection During Anesthesia
    bioRxiv preprint doi: https://doi.org/10.1101/2020.09.05.284075; this version posted September 6, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. 1 Alfaxalone activates Human Pregnane-X Receptors with greater efficacy than Allopregnanolone: an in-vitro study with implications for neuroprotection during anesthesia. Juliet.M. Serrao PhD¶, and Colin.S. Goodchild PhD*,¶, Drawbridge Pharmaceuticals Pty Ltd, Malvern, Victoria, Australia *Corresponding Author: Email: [email protected] (CSG) ¶ These authors contributed equally to this work: planning of the experiments; collating and analyzing data; writing of the manuscript. Data presented herein were submitted to the meeting of the International Research Society planned for May 2020 but then cancelled because of COVID19 pandemic Funding This project was funded by Drawbridge Pharmaceuticals Pty Ltd. Abbreviated Title: alfaxalone activates pregnane-X receptors Conflicts of Interests Juliet M Serrao and Colin S Goodchild both have equity interests in Drawbridge Pharmaceuticals. Both are cited on Phaxan™ patents as inventors and they are both Directors and owners of Drawbridge Pharmaceuticals to which the Phaxan™ patents have been assigned. Abstract Background Alfaxalone is a fast acting intravenous anesthetic with high therapeutic index. It is an analogue of the naturally-occurring neurosteroid, allopregnanolone which has been bioRxiv preprint doi: https://doi.org/10.1101/2020.09.05.284075; this version posted September 6, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.
    [Show full text]
  • ALFAXAN MULTIDOSE- Alfaxalone Injection, Solution Jurox Pty
    ALFAXAN MULTIDOSE- alfaxalone injection, solution Jurox Pty. Limited ---------- ALFAXAN MULTIDOSE NADA 141-342, Approved by FDA For Animal Use Only Alfaxan® Multidose CIV (alfaxalone) 10 mg/mL Intravenous injectable anesthetic for use in cats and dogs CAUTION: Federal law restricts this drug to use by or on the order of a licensed veterinarian. DESCRIPTION ALFAXAN MULTIDOSE (alfaxalone) is a neuroactive steroid molecule with properties of a general anesthetic. Alfaxalone is chemically described as 3-α-hydroxy-5-α-pregnane-11, 20-dione, and has a molecular weight 332.5. The primary mechanism for the anesthetic action of alfaxalone is modulation of neuronal cell membrane chloride ion transport, induced by binding of alfaxalone to GABAA (gamma- aminobutyric acid) cell surface receptors. INDICATIONS ALFAXAN MULTIDOSE is indicated for the induction and maintenance of anesthesia and for induction of anesthesia followed by maintenance with an inhalant anesthetic, in cats and dogs. DOSAGE AND ADMINISTRATION Administer by intravenous injection only. For induction, administer ALFAXAN MULTIDOSE over approximately 60 seconds or until clinical signs show the onset of anesthesia, titrating administration against the response of the patient. Rapid administration of ALFAXAN MULTIDOSE may be associated with an increased incidence of cardiorespiratory depression or apnea. Apnea can occur following induction or after the administration of maintenance boluses of ALFAXAN MULTIDOSE. The use of preanesthetics may reduce the ALFAXAN MULTIDOSE induction dose. The choice and the amount of phenothiazine, alpha2-adrenoreceptor agonist, benzodiazepine or opioid will influence the response of the patient to an induction dose of ALFAXAN MULTIDOSE. When using ALFAXAN MULTIDOSE, patients should be continuously monitored, and facilities for the maintenance of a patent airway, artificial ventilation, and oxygen supplementation must be immediately available.
    [Show full text]
  • Chapter 3 T&L
    Chapter 3 Anesthetic Agents and Adjuncts 1 Chapter 3 Anesthetic Agents and Adjuncts Propofol, etomidate, and alfaxalone are used only in small animals, small ruminants, and neonates of any species, but not in adult large animals because of the high expense of these agents. The ultra-short injectable barbiturate anesthetics are no longer used in general practice in the US due to recent changes in anesthetic practice and limited availability. 2 Chapter 3 Anesthetic Agents and Adjuncts Since its introduction to the veterinary market almost two decades ago, its popularity has gradually increased, and now it is the most commonly used ultra– short-acting injectable agent in small animals for brief procedures or for anesthetic induction before intubation and maintenance with inhalant agents. 3 Chapter 3 Anesthetic Agents and Adjuncts The propofol macroemulsion contains propofol at a concentration of 10 mg/mL as well as egg lecithin, glycerin, and soybean oil. It has a milky appearance but is given by the IV route and consequently is the sole exception to the general rule that milky liquids should never be given intravenously. Although the mode of action is not completely understood, propofol appears to affect GABA receptors in a similar manner to other hypnotics. Propofol has a rapid onset and short duration of action because it is highly fat-soluble. Propofol is rapidly taken up by vessel-rich tissues such as the brain, heart, liver, and kidneys but is very quickly redistributed to muscle and fat and is subsequently rapidly metabolized. This accounts for the rapid recovery and minimal residual sedative effects seen even after repeated injections.
    [Show full text]
  • Federal Register/Vol. 78, No. 57/Monday, March 25, 2013
    Federal Register / Vol. 78, No. 57 / Monday, March 25, 2013 / Proposed Rules 17895 22,109 hours due to this proposed 1. The panel transcript and other being placed in commercial regulatory change. meeting materials are available on distribution. FDA’s Web site at http://www.fda.gov/ IX. Proposed Effective Date Dated: March 19, 2013. AdvisoryCommittees/ Leslie Kux, FDA is proposing that any final order CommitteesMeetingMaterials/ Assistant Commissioner for Policy. based on this proposal become effective MedicalDevices/ on the date of its publication in the MedicalDevicesAdvisoryCommittee/ [FR Doc. 2013–06723 Filed 3–22–13; 8:45 am] Federal Register or at a later date if CirculatorySystemDevicesPanel/ BILLING CODE 4160–01–P stated in the final order. ucm240575.htm. X. Codification of Orders List of Subjects in 21 CFR Part 870 DEPARTMENT OF JUSTICE Prior to the amendments by FDASIA, Medical devices. section 515(b) of the FD&C Act provided Drug Enforcement Administration Therefore, under the Federal Food, for FDA to issue regulations to require Drug, and Cosmetic Act and under approval of an application for premarket 21 CFR Part 1308 authority delegated to the Commissioner approval for preamendments devices or of Food and Drugs, it is proposed that [Docket No. DEA–370] devices found substantially equivalent 21 CFR part 870 be amended as follows: to preamendments devices. Section Schedules of Controlled Substances: 515(b) of the FD&C Act, as amended by PART 870—CARDIOVASCULAR Placement of Alfaxalone into Schedule FDASIA, provides for FDA to require DEVICES IV approval of an application for premarket AGENCY: approval for such devices by issuing a ■ 1.
    [Show full text]